[CAS NO. 2421117-98-6]  BC-DXI-843

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2421117-98-6]

Catalog
HY-136431
Brand
MCE
CAS
2421117-98-6

DESCRIPTION [2421117-98-6]

Overview

MDL-
Molecular Weight546.66
Molecular FormulaC28H26N4O4S2
SMILESCOC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2

For research use only. We do not sell to patients.

Summary

BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC 50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC 50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer [1] .


IC50 & Target

IC50: 0.92 μM (AIMP2-DX2), IC50: >100 μM (AIMP2) [1]


In Vitro

BC-DXI-843 (0.0316-31.6 μM; 72 hours) suppresses cancer cell proliferation in a DX2-dependent manner. The EC 50 in A549 cells is 1.20 μM, which is similar to the IC 50 for inhibition of DX2. However, no inhibition of WI-26 cells is observed, suggesting that BC-DXI-843 specifically reduces the viability of cancer cells [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay [1]

Cell Line: A549 cancer cells and WI-26 normal cells
Concentration: 0.0316, 0.1, 0.316, 1, 3.16, 10, 31.6 μM
Incubation Time: 72 hours
Result: The EC 50 in A549 cells was 1.20 μM. No inhibition of WI-26 cells was observed.

In Vivo

BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates in vivo efficacy in a tumor xenograft mouse model (H460 cells) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 7-week-old female BALB/cSLC-nu/nu mice bearing H460 cells xenograft [1]
Dosage: 50 mg/kg
Administration: Intraperitoneally administered; every other day for 15 days
Result: The embedded tumor volume gradually declined after BC-DXI-843administration, but no changes in body weight were observed. The weight of the excised tumors after sacrifice had decreased in mice.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 457.32 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8293 mL 9.1465 mL 18.2929 mL
5 mM 0.3659 mL 1.8293 mL 3.6586 mL
10 mM 0.1829 mL 0.9146 mL 1.8293 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution

* All of the co-solvents are available by MCE.